NEW YORK (GenomeWeb) – Vela Diagnostics said on Friday that the Sentosa SX101 instrument has been approved by the Taiwan Food and Drug Agency for in vitro diagnostic use.
The Sentosa SX101 is a multi-purpose liquid handling platform that can process 21 separate sample types. It features open channel capabilities for automated sample extraction, PCR setup, next-generation sequencing library preparation, and Sanger sequencing cleanup. The platform is validated for use with Vela's automated and integrated PCR and NGS workflow.
With the approval, Vela Diagnostics said it plans to enter the IVD market and expand its approved portfolio in Taiwan.
In November, Singapore-based Vela said that its Sentosa SX Cell-Free DNA Kit for use on the SX101 platform garnered CE marking for IVD use.